

**(12)**

**EUROPEAN PATENT APPLICATION**

**(21) Application number:** 86108941.5

**(51) Int. Cl.:** **C 07 D 211/22**  
**A 61 K 31/445**

**(22) Date of filing:** 01.07.86

**(30) Priority:** 02.07.85 US 751419

**(43) Date of publication of application:**  
14.01.87 Bulletin 87/3

**(84) Designated Contracting States:**  
AT BE CH DE FR GB IT LI LU NL SE

**(71) Applicant:** MERRELL DOW PHARMACEUTICALS INC.  
2110 E. Galbraith Road  
Cincinnati Ohio 45215(US)

**(72) Inventor:** Carr, Albert A.  
6693 East Farm Acres Drive  
Cincinnati Ohio 45237(US)

**(72) Inventor:** Wiech, Norbert L.  
6296 Crittenden Drive  
Cincinnati Ohio 45244(US)

**(74) Representative:** Vossius & Partner  
Siebertstrasse 4 P.O. Box 8607 67  
D-8000 München 86(DE)

**(54) N-Aralkyl piperidinemethanol derivatives.**

**(57)** This invention relates to a new class of compounds having important biochemical and pharmacological properties. More particularly, this invention relates to N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5HT<sub>2</sub> receptor site, and to the processes for their preparation and use.

**EP 0 208 235 A1**

# VOSSIUS & PARTNER

0208235..

PATENTANWÄLTE  
EUROPEAN PATENT ATTORNEYS

SIEBERTSTRASSE 4 · 8000 MÜNCHEN 88 · PHONE: (089) 47 40 76  
TELEX 529 453 VOPAT D TELEFAX (089) 47 20 01 (GR. II+III)


Our Ref.: U 689 EP  
Case: C-34,227A EP  
Merrell Dow Pharmaceuticals, Inc.  
Ohio, USA

July 1, 1986

## N-Aralkyl piperidinemethanol derivatives

This invention relates to a new class of compounds having important biochemical and pharmacological properties. More particularly, this invention relates to N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5HT<sub>2</sub> receptor site, and to the processes for their preparation and use.

The compounds of this invention are represented by the general formula I



I

including optical isomers and mixtures thereof, the pharmaceutically acceptable salts thereof, wherein  $n$  is 2, 3 or 4 and each of  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  independently represents hydrogen,  $C_{1-6}$  alkyl, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$  alkoxy, or amino.

Representative of the  $R^1$  to  $R^4$  substituents for  $C_{1-6}$  alkyl are methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, pentyl, hexyl, cyclopropyl, cyclopentyl with methyl and ethyl being preferred. All halogens are embraced with fluoro and chloro being preferred. Representative  $C_{1-6}$  alkoxy substituents are methoxy, ethoxy, isopropoxy and such of the aforementioned alkyl groups attached thru an oxygen. In those instances wherein  $R^1$  to  $R^4$  are other than hydrogen, the substituents may be located at any position, (ortho, meta or para) but para is preferred for monosubstituted phenyl moieties. The 2,3-, 2,4-, 2,5-, 3,4-, or 3,5- disubstituted phenyl moieties are embraced herein. The compounds of Formula I contain an asymmetric carbon atom and thus exist in optically isomeric forms. Embraced within this invention are the individual optical isomers and the mixtures thereof. Such mixtures may readily be separated by standard techniques well known in the art.


Preferred are the following compounds of the general formula (I):

The compounds wherein  $n$  is 2; the compounds wherein  $n$  is 3; the compounds wherein  $R^3$  and  $R^4$  are hydrogen; the compounds wherein  $R^1$  to  $R^4$  are hydrogen; the compounds wherein  $R^1$  and  $R^2$  are methoxy and  $R^3$  and  $R^4$  are hydrogen; the compounds wherein  $R^1$  is methoxy and each of  $R^2$ ,  $R^3$  and  $R^4$  is hydrogen; the compounds wherein  $R^1$  and  $R^2$  are halogen and  $R^3$  and  $R^4$  are hydrogen; and the compounds wherein  $R^1$  is methyl and  $R^2$ ,  $R^3$  and  $R^4$  are hydrogen.


The preparation of the compounds of this invention may be achieved by standard chemical reactions analogously known in the art.

The compounds of the general formula I may be prepared by one of the following processes:


A) the chemical reduction of a compound of the formula.



B) the alkylation of a compound of the formula




with a reactive derivative having the formula




IV

wherein X is a reactive moiety, preferably a halide, tosylate, mesylate or a functional equivalent thereof, or

(C) the reaction of a Grignard reagent V with an aldehyde of the formula VI



V




VI

and hydrolyzing the reaction product,


wherein  $R^1$  to  $R^4$  and  $n$  is defined as above.

Especially preferred is the compound of formula VII




This compound can be obtained according to one of the following methods:


A) the chemical reduction of a compound of the formula



B) the alkylation of the compound of formula IX




with an alkylating agent of the formula X



wherein the X-substituent is a halide, tosylate, mesylate or a functional equivalent thereof, or

(C) the reaction of a Grignard reagent XI with an aldehyde of the formulae XII




and hydrolyzing the reaction product.

To obtain the compounds of formula IIa it is preferred to N-alkylate an appropriately  $R^1, R^2$ -substituted phenyl 4-piperidinemethanone (XIII) to produce a  $R^1, R^2$  phenyl-[-1- $R^3, R^4$ -phenylalkyl-4-piperidinyl] methanone intermediate (IIa), which intermediate is then chemically reduced to the desired product (I). Alternately the 4-piperidinones (XIII) may be chemically reduced to their alcohols (III) and these intermediates may be N-alkylated to the desired products (I). The chemical reduction of the ketones to their corresponding alcohols may be effected by standard reduction procedures such as by catalytic hydrogenation or metal hydride reduction preferably with sodium or potassium borohydride. In either case in those instances wherein any  $R^1$  to  $R^4$  substituent represents a reactive hydroxy group then such group should first be protected (using such standard protecting groups as acetate, trifluoroacetate, benzyloxy, benzyloxycarbonyl and the like) and then, following the foregoing N-alkylation-reduction reactions, the protecting group is removed. Standard techniques for protecting and de-protecting hydroxy functions are well known in the art. Analogously in those instances wherein any  $R^1$  to  $R^4$  group represents an amino moiety, it is preferred to prepare the appropriate nitro analog and, as a last step, reduce the nitro group to the desired amino moiety. The foregoing reactions may conveniently be depicted by the following reaction scheme.



Reaction Scheme A



wherein X is a suitable leaving group (e.g., halide, tosylate or other functional equivalent thereof) and n, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined for compounds of Formula I.

The N-alkylation procedures are effected by reacting about equimolar quantities of the N-alkylating reactants (IV) with an appropriately substituted 4-piperidine-methanol (III) or 4-piperidinylmethanone (XIII), in a suitable

solvent, in the presence of an acid acceptor (e.g., the carbonates or bicarbonates of potassium or sodium, or an excess of the piperidine reactant), optionally with a small amount of potassium iodide being present. Suitable solvents are toluene, xylene, chlorobenzene, N, N-dimethylformamide, N, N-dimethylacetamide, ketones (acetone, butanone, MIBK, cyclohexanone, cyclopentanone, etc.) and alcohols (ethanol, propanol, butanol, etc.) The reaction mixture is heated over a wide range of temperatures (50°C-180°C) although it is preferred to heat at reflux temperatures of the reaction mixture. The reaction is continued until completed, generally a period of several hours to several days.

After completion of the reaction, the reaction mixture is filtered, the product optionally converted to its mineral or organic acid salt and the desired product is recrystallized by techniques well-known in the art. Suitable solvents for recrystallization are methanol, ethanol, isopropanol, butanone, acetone, ethyl acetate, diethylether and the like.

The intermediate R<sup>1</sup>,R<sup>2</sup>-substituted phenyl 4-piperidyl ketones (XIII) used in the preparation of the compounds of Reaction Scheme A may be prepared by a Friedel-Craft reaction of benzene or a R<sup>1</sup>,R<sup>2</sup> substituted benzene with isonipecotic acid chloride HCl or N-(trifluoroacetyl) isonipecotic trifluoroacetic anhydride followed by aqueous potassium carbonate hydrolysis in the latter case. Reaction of a substituted phenyl Grignard reagent with 4-cyanopiperidine (prepared by hydrolyzing N-trifluoroacetyl-4-cyanopiperidine) will also yield the intermediate ketones.

Alternative methods of synthesis of the compounds of this invention include the reactions of either a  $R^1, R^2$ -phenylmagnesium halide (IV) or a  $R^1, R^2$ -substituted phenyl lithium reactant with 1-( $\omega$ - $R^3, R^4$ -phenyl alkyl)-4-piperidine carboxaldehyde (VI). Another alternative procedure includes the catalytic hydrogenation of an  $\alpha$ -( $R^1, R^2$ -phenyl-methanol)-1-( $R^3, R^4$ -phenylalkyl)pyridinium halide, or its ketone analog (IIc), to <sup>the</sup> desired product. Still another method is the chemical reduction of a  $R^1, R^2$ -phenyl[1-(12- $R^3, R^4$ -phenacyl)-4-piperidinyl]-methanone (IIId) to the desired products of this invention. For these foregoing reactions standard procedures well known in the art may be used in the preparation of the necessary intermediates as well as for the final step producing the desired products.

Having taught the general methods for the preparation of the compounds of this invention the following examples typify the preferred routes of preparation.

EXAMPLE 1

ALPHA-PHENYL-1-(2-PHENYLETHYL)-4-PIPERIDINEMETHANOL HCl

Step A: Phenyl[1-(2-phenylethyl)-4-piperidinyl]-methanone HCl. A reaction mixture containing phenyl(4-piperidinyl)methanone (20.5 g, 0.108 mol),  $K_2CO_3$  (33.17 g, 0.18 mol), potassium iodide (0.2 g) and 2-bromoethyl benzene (22.2 g, 0.12 mol, 16.4 ml) in toluene (250 ml) was stirred at reflux temperature for 66 h. The reaction

0208235

5 mixture was filtered and the filtrate concentrated to a residue which was dissolved in dry Et<sub>2</sub>O (500 ml) and treated dropwise with a solution of HCl (0.11 mol) in EtOAc. The resultant precipitate was recrystallized from EtOH:CH<sub>3</sub>OH, 4:1 (500 ml) to give phenyl[1-(2-phenylethyl)-4-piperidinyll-methanone hydrochloride, mp 258-260°C.

10 Step B: A solution of phenyl[1-(2-phenylethyl)-4-piperidinyll-methanone (11.0 g, 0.037 mol) in absolute EtOH (150 ml) was stirred at room temperature and treated portionwise with NaBH<sub>4</sub> (2.84 g, 0.075 mol) and was stirred overnight (16 h). The reaction mixture was concentrated at reduced pressure to give a residue which was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (250 ml) and 10% NaOH solution (100 ml). The aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub> 15 (2 X 50 ml) and the combined extracts washed with saturated NaCl solution (100 ml) and dried over MgSO<sub>4</sub>. The mixture was filtered and concentrated to give a solid (10 g) which was dissolved in dry Et<sub>2</sub>O/EtOAc (1:1, 350 ml) and treated with HCl (0.034 mol) dissolved in EtOAc/CH<sub>3</sub>OH 20 (3:1, 20 ml). The resultant precipitate was recrystallized twice from methanol/butanone to give - phenyl-1-(2-phenyl-ethyl)-4-piperidinemethanol hydrochloride, mp 141-143.5°C.

EXAMPLE 2

25 ALPHA-PHENYL-1-(2-PHENYLETHYL)-4-PIPERIDINEMETHANOL

30 A mixture of alpha-phenyl-4-piperidinemethanol (1.5 g, 7.8 mmol), 2-bromoethyl benzene (1.1 ml, 8.0 mmol) and potassium carbonate (1.1 g, 8.0 mmol) in dry DMF (20 ml) was heated at 80°C over the weekend (60 h). The excess DMF was distilled off at reduced pressure and the residue was dissolved in ethyl acetate. The organic phase was washed with H<sub>2</sub>O (3 X 100 ml), saturated aqueous NaCl (1 X

100 ml), dried ( $\text{MgSO}_4$ ), filtered and evaporated to give a pale yellow oil which eventually crystallized. After recrystallization from ethyl acetate-hexane, a white crystalline solid was obtained, mp 125-128°C.

5

EXAMPLE 3ALPHA-PHENYL-1-(3-PHENYLPROPYL)-4-PIPERIDINEMETHANOL

10        Step A: Phenyl [1-(3-phenylpropyl)-4-piperidinyl]-methanone hydrochloride. A solution of phenyl (4-piperidinyl)methanone (18.1 g, 0.096 mol) was dissolved in toluene (200 ml) containing 1-bromo-3-phenylpropane (21.9 g, 0.11 mol, 16.7 ml),  $\text{K}_2\text{CO}_3$  (30.4 g, 0.22 mol) and KI (0.2 g) and was refluxed for 64 h. The reaction mixture was filtered and concentrated to give a light yellow oil. This material was dissolved in toluene/EtOAc (1:1) and  
15        treated with HCl (0.096 mol) dissolved in  $\text{CH}_3\text{OH}$ /EtOAc (2:5, 35 ml) to give a precipitate which was filtered off and recrystallized twice from EtOH/ $\text{Et}_2\text{O}$  (150 ml) to give phenyl[1-(3-phenylpropyl)-4-piperidinyl]-methanone hydrochloride, mp 199-200°C.

20

Step B: To a stirred solution of phenyl[1-(3-phenylpropyl)-4-piperidinyl]-methanone hydrochloride (6.8 g, 0.02 mol) in absolute ethanol (120 ml) was added sodium methoxide (1.08 g, 0.04 mol) followed by sodium borohydride (1.51 g, 0.04 mol). The reaction mixture was  
25        stirred for 72 h and then concentrated at reduced pressure to a solid residue. This material was stirred with

0208235

aqueous 10% NaOH for 1 h and then extracted with toluene (2 X 50 ml). The extracts were washed with water and then saturated NaCl solution. The toluene solution was dried over MgSO<sub>4</sub>, filtered and concentrated to a colorless oil. This material was dissolved in dry Et<sub>2</sub>O (50 ml) and treated with a solution of HCl (0.02 mol) in CH<sub>3</sub>OH/EtOAc (1:4, 12.5 ml). The resultant precipitate was dissolved in water, basified using 10% aqueous NaOH and extracted into toluene. The toluene solution was washed with saturated aqueous NaCl dried over MgSO<sub>4</sub>, filtered and concentrated to a solid. This material was flash chromatographed on a 2.5 X 6.0 inch silica gel column, and eluted with CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub> (1:9). The resultant fractions (7-9) eventually solidified and were recrystallized from acetone to give alpha-phenyl-1-(3-phenylpropyl)-4-piperidinemethanol, mp 87-88°C.

EXAMPLE 4

ALPHA-(4-METHYLPHENYL)-1-(2-PHENYLETHYL)  
-4-PIPERIDINEMETHANOL HCl

Step A: (4-Methylphenyl)[1-(2-phenylethyl)-4-piperidinyl]-methanone HCl. A mixture containing 4-(methylphenyl)(4-piperidinyl)methanone (10.5 g, 0.052 mol), 2-bromoethyl benzene (11.1 g, 0.06 mol, 8.2 ml) in dry DMF (125 ml) was stirred at 100°C for 23 h. The cooled reaction mixture was poured into H<sub>2</sub>O (600 ml) and extracted with toluene (4 X 200 ml). The extracts were washed with H<sub>2</sub>O (2 X 100 ml) saturated aqueous NaCl (100 ml) and dried over MgSO<sub>4</sub>. The mixture was filtered and the filtrate concentrated to a solid residue which was dissolved in dry Et<sub>2</sub>O and filtered. The filtrate was treated with a solution of HCl (0.052 mol) in CH<sub>3</sub>OH/EtOAc (9:20, 29 ml). The mixture was cooled and filtered to give a light tan powder. The solid was recrystallized

twice from EtOH/Et<sub>2</sub>O to give (4-methylphenyl)[1-(2-phenylethyl)-4-piperidinyl]-methanone hydrochloride, which contains 0.4 mol of water of hydration and melts at 261-263°C.

5        Step B: A solution of (4-methylphenyl)[1-(2-phenyl-  
ethyl)-4-piperidinyl]-methanone hydrochloride (9.5 g,  
0.028 mol) in absolute ethanol (350 ml) was treated first  
by the addition of NaOCH<sub>3</sub> (1.62 g, 0.03 mol) and then,  
portionwise, with sodium borohydride (2.27 g, 0.06 mol)  
10 and stirred at room temperature for 18 h. The reaction  
mixture was concentrated to a solid and stirred with 10%  
aqueous NaOH. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 X  
50 ml). The CH<sub>2</sub>Cl<sub>2</sub> solution was washed with water and  
then saturated NaCl solution, and dried over Na<sub>2</sub>SO<sub>4</sub>.  
15 After filtering off the Na<sub>2</sub>SO<sub>4</sub>, the filtrate was  
concentrated to a solid. This material was dissolved in  
EtOAc/Et<sub>2</sub>O (1:1, 200 ml) and treated with a solution of  
HCl (0.023 mol) in CH<sub>3</sub>OH/EtOAc (3:10, 13 ml). The  
resulting precipitate was twice recrystallized from  
20 butanone containing a small amount of CH<sub>3</sub>OH to give alpha-  
(4-methylphenyl)-1-(2-phenylethyl)-4-piperidinemethanol  
hydrochloride, mp 181-183°C.

#### EXAMPLE 5

#### ALPHA-(4-METHOXYPHENYL)-1-(2-PHENYLETHYL)- 25        -4-PIPERIDINEMETHANOL HCl

Step A: (4-Methoxyphenyl)[1-(2-phenylethyl)-4-  
piperidinyl]-methanone HCl. A reaction mixture containing  
4-(methoxyphenyl)(4-piperidinyl)methanone (10.3 g, 0.047  
mol), 2-bromoethylbenzene (9.57 g, 0.052 mol, 7.1 ml) and  
30 K<sub>2</sub>CO<sub>3</sub> (15.2 g, 0.11 mol) in dry DMF (100 ml) was stirred  
at 90° for 65 h. The cooled reaction mixture was poured

0208235

into H<sub>2</sub>O (500 ml) and extracted with toluene (3 X 100 ml). The extracts were washed with H<sub>2</sub>O, saturated aqueous NaCl solution and dried over MgSO<sub>4</sub>. The mixture was filtered and the filtrate concentrated to a residue which was trituated with hexane and filtered. The resulting precipitate (0.022 mol) was dissolved in dry Et<sub>2</sub>O and treated with a solution of HCl (0.022 mol) in CH<sub>3</sub>OH/EtOAc (2:5, 14 ml) to give a precipitate which was twice recrystallized from EtOH/Et<sub>2</sub>O, to give (4-methoxyphenyl)[1-(2-phenylethyl)-4-piperidinyl]-methanone hydrochloride, mp 238.5-239.5°C.

Step B: A solution of (4-methoxyphenyl)[1-(2-phenylethyl)-4-piperidinyl]-methanone hydrochloride (3.5 g, 9.7 mmol) in absolute EtOH (75 ml) was treated with sodium methoxide (0.53 g, 9.7 mmol) followed by sodium borohydride (1.08 g, 20 mmol) and the mixture stirred for 42 h at room temperature. The reaction mixture was filtered and the filtrate concentrated to a solid residue which was dissolved in absolute Et<sub>2</sub>O and treated with HCl (9.7 mmol) dissolved in CH<sub>3</sub>OH/EtOAc (1:3, 8 ml). The resulting precipitate was filtered and recrystallized from CH<sub>3</sub>OH/Et<sub>2</sub>O to give alpha-(4-methoxyphenyl)-1-(2-phenylethyl)-4-piperidinemethanol hydrochloride, mp 162.5-164°C.

#### EXAMPLE 6

#### ALPHA-[4-(1-METHYLETHYL)PHENYL]1-(2-PHENYLETHYL)PIPERIDINYL-METHANOL HCl

Step A: [4-(1-methylethyl)phenyl][1-(2-phenylethyl)-piperidinyl]-methanone HCl. A solution of [4-(1-methylethyl)phenyl](4-piperidinyl)-methanone (43 g, 0.19 mol) in toluene (500 ml) was treated with 2-bromoethylbenzene (37 g, 0.2 mol), K<sub>2</sub>CO<sub>3</sub> (25 g, 0.18 mol), KHCO<sub>3</sub> (25 g, 0.25 mol) and potassium iodide (0.1 g) and the mixture heated



on a steam bath for 68 h. The reaction mixture was filtered and the filtrate treated with ethereal hydrogen chloride until acid to congo red indicator paper. The resultant precipitate was filtered off and recrystallized twice from CH<sub>3</sub>OH/butanone to give [4-(1-methylethyl)-phenyl][1-(2-phenylethyl)piperidinyl-methanone hydrochloride, mp 251-253°C. By following the sodium borohydride reduction procedure of the foregoing example there is obtained the desired product of this example.

#### EXAMPLE 7

##### ALPHA-(3,5-DIMETHYLPHENYL)-1-(2-PHENYLETHYL)

##### ALPHA-4-PIERIDINEMETHANOL

Step A: (3,5-Dimethylphenyl)[1-(2-phenylethyl)-4-piperidinyl]-methanone HCl. A solution of 5-bromo-m-xylene (22.3 g, 0.12 mol) in dry THF (50 ml) was added under N<sub>2</sub> to an oven dried 1 L round bottom flask containing Mg turnings (3.0 g, 0.12 mol) and a crystal of I<sub>2</sub> covered with dry THF (50 ml) at a rate such that the THF gently refluxed once the reaction had commenced. After the addition was complete, the mixture was stirred for 1 h at room temperature. At this time the Grignard solution was diluted to 500 ml with dry THF and 4-cyano-1-(2-phenylethyl)piperidine (15.0 g, 0.12 mol) in dry THF (50 ml) was added over a period of 15 min. Dry toluene (250 ml) was added and the mixture refluxed while THF was distilled off until a reaction temperature of 85°C was reached. The mixture was refluxed at this temperature overnight (16 h). It was then cooled in an ice bath and 1N H<sub>2</sub>SO<sub>4</sub> (200 ml) was added dropwise with vigorous stirring. When the addition was complete, the mixture was warmed to room temperature and stirred an additional 3 h. The aqueous phase was separated and washed twice more with

toluene (200 ml) before it was basified with aqueous 2N NaOH and extracted with Et<sub>2</sub>O (3 X 200 ml). The extract was washed with saturated aqueous NaCl (1 X 250 ml), dried (MgSO<sub>4</sub>), filtered and evaporated to give a yellow oil. This oil was distilled (Kugelrohr) to give a yellow glass which crystallized upon standing. This material was recrystallized from ether to give a white crystalline powder, mp 76-78°C.

The hydrochloride salt was prepared by adding the free base to a cold methanol solution containing one equivalent of HCl. This solution was evaporated to dryness and the residue recrystallized from methanol-butanone to give fluffy white crystals, mp 211-214°C.

Step B: To a solution of (3,5-dimethylphenyl)[1-(2-phenylethyl)-4-piperidinyl]-methanone (21.5 g, 66.9 mmol) in methanol (300 ml) cooled in an ice bath was added portionwise with stirring sodium borohydride (2.53 g, 66.9 mmol). The reaction was allowed to warm to room temperature and stirred overnight (16 h). This mixture was evaporated and the residue stirred in Et<sub>2</sub>O, washed with H<sub>2</sub>O (3 X 100 ml), saturated aqueous NaCl (1 X 100 ml), dried (MgSO<sub>4</sub>), filtered and evaporated to give a light yellow solid. This solid was recrystallized from butanone to give a white crystalline solid, mp 150-154°C.

#### EXAMPLE 8

#### 1-(2-PHENYLETHYL)-ALPHA-[3-(TRIFLUOROMETHYL)PHENYL]-4-PIPERIDINEMETHANOL

Step A: [1-(2-Phenylethyl)-4-piperidinyl][3-(trifluoromethyl)-phenyl]-methanone HCl. A solution of 3-bromobenzotrifluoride (17 ml, 0.12 mol) in dry THF (50 ml)

was added under  $N_2$  to an oven dried 1 L round bottom flask containing Mg turnings (3.0 g, 0.12 mol) and a crystal of  $I_2$  covered with dry THF (50 ml) at a rate such that the THF gently refluxed once the reaction had commenced.

5 After the addition was complete, the mixture was stirred for 1 h at room temperature. At this time the Grignard solution was diluted to 500 ml with dry THF and 4-cyano-1-(2-phenylethyl)piperidine (15.0 g, 0.12 mol) in dry THF (50 ml) was added over a period of 15 min. Dry toluene  
10 (250 ml) was added and the mixture refluxed while THF was distilled off until a reaction temperature of  $85^\circ C$  was reached. The mixture was refluxed at this temperature overnight (16 h). It was then cooled in an ice bath and 1N  $H_2SO_4$  (200 ml) was added dropwise with vigorous  
15 stirring. When the addition was complete, the mixture was warmed to room temperature and stirred an additional 1 h. The aqueous phase was separated and washed twice more with toluene (200 ml) before it was basified with aqueous 2N NaOH and extracted with  $Et_2O$  (3 X 200 ml). The extract  
20 was washed with aqueous saturated NaCl (1 X 250 ml), dried ( $MgSO_4$ ), filtered and evaporated to an orange oil. This oil was distilled (Kugelrohr) to give a yellow glass (bp  $120-130^\circ C$ , 1 mm Hg) which crystallized upon standing. This material was recrystallized from  $Et_2O$  to give white  
25 needles, mp  $70-73^\circ C$ .

The hydrochloride salt was prepared by adding a solution of free base in methanol to a cold methanol solution containing one equivalent of HCl. This solution was evaporated to dryness and the residue recrystallized  
30 from methanol-butanone to give a white crystalline solid, mp  $248-251^\circ C$ .

0208235

5        Step B: To a solution of [1-(2-phenylethyl)-4-piperidinyl][3-(trifluoromethyl)-phenyl]-methanone (2.8 g, 7.75 mmol) in methanol (50 ml) cooled in an ice bath was added portionwise sodium borohydride (0.3 g, 7.75 mmol).  
10        The reaction was allowed to warm to room temperature and stirred an additional 4 h. The mixture was evaporated and the residue extracted with Et<sub>2</sub>O, washed with H<sub>2</sub>O (3 X 100 ml), saturated aqueous NaCl (1 X 100 ml), dried (Mg SO<sub>4</sub>), filtered and evaporated to give a white solid. This solid was recrystallized from ether-hexane to give white needles, mp 143-147°C.

EXAMPLE 9

ALPHA-(2,3-DIMETHOXYPHENYL)-1-(2-PHENYLETHYL)-4-PIPERIDINEMETHANOL HCl

15        Step A: 1-(2-Phenylethyl)piperidine-4-carboxaldehyde. To a solution of 4-cyano-1-(2-phenylethyl)-piperidine (6.5 g, 30.3 mmol) in dry toluene (100 ml) cooled in an ice bath was added dropwise 43 ml (43 mmol) of 1M diisobutylaluminum hydride in hexane. After the  
20        addition was complete, the mixture was warmed to room temperature and stirred overnight (16 h). Methanol was added to decompose any unreacted reagent and H<sub>2</sub>O was added with vigorous stirring. The gelatinous aluminum salts were removed by filtration through Celite and the filtrate  
25        extracted with toluene (2 X 100 ml). The extracts were combined, washed with saturated aqueous NaCl, dried (MgSO<sub>4</sub>) filtered and evaporated to give a clear oil. This oil was flash chromatographed on silica gel using acetone as eluent to give product as a clear oil, which was used  
30        without further purification.

Step B: To a solution of veratrole (2.5 ml, 19.6 mmol) in dry THF (150 ml) cooled to 0°C was added 13 ml (20.7 mmol) of 1.6 M n-butyllithium dropwise. This mixture was kept at 0°C for another 5 h before it was cooled to -45°C and 1-(2-phenylethyl)piperidine-4-carboxaldehyde (3.6 g, 16.6 mmol) in dry THF (10 ml) was added dropwise. The mixture was kept at -45°C for 1 h before it was allowed to warm to room temperature and stirred overnight (16 h). The reaction mixture was poured into 5% aqueous NH<sub>4</sub>Cl, extracted with Et<sub>2</sub>O (3 X 100 ml), dried (MgSO<sub>4</sub>), filtered and evaporated to an orange oil.

The hydrochloride salt was prepared by adding a solution of the free base in methanol to a cold methanol solution containing one equivalent of HCl. This solution was evaporated to give a foam which crystallized from a vigorously stirred acetone-hexane solution. Two recrystallizations from methanol-butanone gave pale orange crystals, mp 182-185°C.

#### EXAMPLE 10

#### ALPHA-(3,4-DICHLOROPHENYL)-1-(2-PHENYLETHYL)-4-PIPERIDINEMETHANOL HYDROCHLORIDE

Step A: (3,4-Dichlorophenyl)[1-(2-phenylethyl)-4-piperidinyl]-methanone HCl. A solution of 1-bromo-3,4-dichlorobenzene (10.0 g, 44.2 mmol) in dry THF (50 ml) was added under N<sub>2</sub> to an oven dried 1 L round bottom flask containing Mg turnings (1.2 g, 49.4 mmol) and a crystal of I<sub>2</sub> covered with dry THF (50 ml) at a rate such that the THF gently refluxed once the reaction had commenced. After the addition was completed the mixture was stirred for 1 h at room temperature. At this time the Grignard

0208235

5 solution was diluted to 500 ml with dry THF and 4-cyano-1-(2-phenylethyl)piperidine (9.5 g, 44.2 mmol) in dry THF (50 ml) was added over a period of 15 min. Dry toluene (250 ml) was added and the mixture refluxed while THF was distilled off until a reaction temperature of 80° was reached. The mixture was refluxed at this temperature overnight (16 h). It was then cooled in an ice bath and 1N H<sub>2</sub>SO<sub>4</sub> (200 ml) was added dropwise with vigorous stirring. When this addition was completed, the mixture was warmed to room temperature and stirred an additional 3 h. 10 The aqueous phase was separated and washed twice more with toluene (200 ml), basified with aqueous 2N NaOH and extracted with Et<sub>2</sub>O (3 X 200 ml). The extract was washed with saturated aqueous NaCl (1 X 250 ml), dried (MgSO<sub>4</sub>), 15 filtered and evaporated to give an orange solid. This solid was flashed chromatographed on silica gel using 20% acetone-dichloromethane as eluent and the resultant product triturated with Et<sub>2</sub>O to give a light orange solid.

20 The hydrochloride salt was prepared by adding the free base to a cold methanol solution containing one equivalent of HCl. This solution was evaporated to dryness and the residue recrystallized from methanol-butanone to give a white solid, mp 238-242°C with decomposition.

25 Step B: To a solution of (3,4-dichlorophenyl)[1-(2-phenylethyl)-4-piperdinyll-methanone (1.9 g, 5.2 mmol) in methanol (50 ml) cooled in an ice bath was added portion-wise sodium borohydride (0.6 g, 15.9 mmol). The reaction was allowed to warm to room temperature and stirred an additional 4 h. The mixture was evaporated and the residue stirred in Et<sub>2</sub>O, washed with H<sub>2</sub>O (3 X 100 ml), 30 saturated aqueous NaCl (1 X 100 ml), dried (MgSO<sub>4</sub>), filtered and evaporated to give a white solid.

5       The hydrochloride salt was prepared by adding the  
free base to a cold methanol solution containing one  
equivalent of HCl. This solution was evaporated to give a  
pale yellow foam which crystallized from a vigorously  
stirred acetone-hexane solution. Recrystallization from  
methanol-butanone gave a white solid, mp 161-164°C.

10       In a similar manner, by substantially following the  
teachings of the foregoing examples substituting the  
appropriate reactants there may be produced the following  
compounds.

(4-fluorophenyl)[1-(2-phenethyl)-4-piperidinyl]methanol.

Alpha-phenyl-[1-(4-Phenylbutyl)-4-  
piperidinyl]methanol,

15       Alpha-(3,4-dimethoxyphenyl)[1-(2-Phenylethyl)-4-  
piperidinyl]methanol,

Alpha-phenyl[1-(4-aminophenylethyl)-4-piperidinyl  
methanol,

Alpha-phenyl[1-(4-methoxyphenylethyl)]-4-piperidinyl  
methanol,

20       Alpha-(4-methoxyphenyl)-[1-(4-methoxyphenylethyl)]-4-  
piperidinyl methanol,

Alpha-(2,3-dimethoxyphenyl)-[1-(4-  
methoxyphenylethyl)]-4-piperidinyl methanol,

25       Alpha-phenyl[1-(4-methylphenylethyl)]-4-piperidinyl  
methanol,

0208235

Alpha-phenyl[1-(4-fluorophenylethyl)]-4-piperidinyl  
methanol,

Alpha-(4-hydroxyphenyl)-[1-(2-phenylethyl)]-4-  
piperidinyl methanol,

5 Alpha-(3,4-dihydroxyphenyl)-[1-(2-phenylethyl)]-4-  
piperidinyl methanol,



0208235

5 The compounds of this invention have very interesting  
biochemical and pharmacological activities. The compounds  
(I) are potent and selective serotonin antagonists in  
that, at relatively low doses, they inhibit the binding of  
serotonin at the 5HT<sub>2</sub> receptor sites with little, if any,  
inhibition of the binding of serotonin at the 5HT<sub>1</sub> re-  
ceptor sites. Further, since it has been reported that  
the receptor subserving the serotonin vasoconstriction is  
of the 5HT<sub>2</sub> subtype, the serotonin antagonism at the 5HT<sub>2</sub>  
receptor sites of the compounds of this invention will  
10 also be useful in the treatment of such serotonin-mediated  
disease states as anorexia nervosa, variant angina,  
Raynaud's phenomena and coronary vasospasms and in the  
prophylactic treatment of migraine.

15 Using standard laboratory in vitro and in vivo  
methodology, either alone or in comparison studies with  
known serotonin antagonists, it is readily seen that the  
compounds of this invention are potent serotonin antag-  
onists at the 5HT<sub>2</sub> receptor sites with virtually no act-  
ivity at the 5HT<sub>1</sub>, adrenergic alpha-1, dopamine D-2 or  
20 muscarinic cholinergic receptors. By contrast with such  
well-known agents as ketanserin, methysergide and cypro-  
heptadine such selectivity is, indeed, unique.

25 For example, utilizing anesthetized ganglion-blocked  
dog to assess alpha-adrenergic and serotoninergic blockade,  
it is to be found that the compounds of this invention  
antagonize the effects of a serotonin challenge in vivo  
(i.e., eliminated the pressor response to serotonin) and  
had no effect on the phenylephrine in vivo challenge thus  
demonstrating in vivo antagonism of the vascular effects  
30 of serotonin which is accompanied with little, if any  
alpha-adrenergic receptor blocking activity. Ketanserin  
on the other hand will block both.

As with both ketanserin and cyproheptadine, the compounds of this invention were effective in blocking the effects of serotonin as measured in the standard 5-hydroxytryptophan-induced "head twitch" in vivo (mice) laboratory model. Further, contrary to findings with ketanserin, it is to be found that compounds of this invention have no significant anti-hypertensive activity in conscious spontaneously hypertensive rats (SHR). However, in anesthetized spontaneously hypertensive rats, compounds of this invention produce a marked decrease in systolic blood pressure.

In summary, based on comparative studies it is expected that in view of their selectivity in exerting potent anti-serotonin effects, the compounds of this invention will exhibit an improved pharmacologically active profile over that exhibited by ketanserin (a compound being clinically evaluated for use in the treatment of cardiovascular diseases, e.g. hypertension, peripheral vascular disease, thrombotic episodes and cardiopulmonary emergencies) for, although a potent 5HT<sub>2</sub> antagonist, it is non-selective in that it blocks H-1 and alpha-1 adrenergic receptors. Similarly, because of their numerous side effects the marketed serotonin antagonists methysergide and cyproheptadine have a less desirable pharmacological profile than that possessed by the compounds of this invention.

In addition, the compounds of this invention exhibit topical anesthetic activity similar in effect to that of procaine, and they also exhibit an analgesic effect in the standard acetic-acid-induced writhing test.

5 The compounds (I) exert their serotonin antagonist-  
induced pharmacological activities at 1-10 mg/kg when  
parenterally administered and at 0.1-3 mg/kg when intra-  
venously administered. On comparative bases it is ex-  
pected that the compounds of this will exert their end-use  
therapeutic effects at 30-600 mg per day (on 70 kg body  
weight), this amount being administered in divided doses.  
In each specific instance, depending on the severity and  
type of disease state, the attending diagnostician will  
10 readily be able to determine the dosage and its frequency  
of administration.

15 Further, the compounds of this invention also exhibit  
significant anti-fibrillatory effects when tested  
according to standard laboratory techniques, said  
techniques being useful in the determination of anti-  
arrhythmic properties. Thus, the compounds particularly,  
alpha-phenyl-1-(2-phenethyl)-4-piperidinemethanol (and its  
salts), are useful in the prevention and/or treatment of  
ventricular fibrillatory aberrations due to acute  
20 myocardial ischemia. Other arrhythmic conditions  
contemplated include ventricular tachycardia,  
atrioventricular nodal beats, auricular flutter, auricular  
fibrillation and premature ventricular contractions.

25 The compounds of this invention exert their anti-  
arrhythmic pharmacological activities at 1-100 mg/kg when  
enterally administered and at 0.1-10 mg/kg when  
administered intravenously.

0206235

5       The compounds of this invention, as defined by  
Formula I, can be administered as such, or can be ad-  
ministered in the form of a composition comprising the  
active ingredient and any of the commonly used pharma-  
ceutical carriers. These carriers must be compatible with  
the active ingredient, and can be either solid or liquid,  
therapeutically active or inert. By using such carriers,  
one can make these compositions in the form of tablets,  
capsules, powders, suppositories, oral suspensions, or  
10       syrups. The compositions can also be made in the form of  
sterile solutions which are suitable for injection. The  
compositions will contain from 1% to 95% by weight of  
active compound, and from 5% to 99% by weight of a  
suitable pharmaceutical carrier. These ranges, however,  
15       are not critical and can be varied as desired according to  
the circumstances.

20       A sterile solution suitable for injection is prepared  
by admixing from 0.5 to 5 parts by weight of the active  
ingredient, preferably in the form of its salt, and from  
95 to 99.5 parts by weight of water or isotonic saline  
solution at a temperature and for time sufficient to  
dissolve the active ingredient. This solution is then  
sterilized by filtration or by the application of heat.

25       These injectable solutions can be prepared with a  
high concentration of active ingredient. The solution is  
then diluted to a desired concentration before it is used.

30       The compounds of Formula I can also be administered  
in the form of hard or soft gelatin capsules. These  
capsules are filled with the proper amount of active  
ingredient and solid filler, such as starch, gelatin,

0208235

lactose, talc, stearic acid, or magnesium stearate. Such a capsule can contain from 5 to 50 milligrams of active material, thus providing a minimum dose of active ingredient in a form convenient for oral administration.

5           The compounds of Formula I, when mixed with a  
suitable carrier, can also be formulated as tablets. Such  
carriers must be compatible with the active ingredient and  
can be the carriers mentioned for use with capsules, or  
can be such binders or fillers as cornstarch, acacia,  
10           gelatin, or cellulosic materials. Generally, any of the  
tableting materials conventionally used in pharmaceutical  
practice can be employed if there is no incompatibility  
with the active ingredient.

15           The tablets are made by admixing the active in-  
gredient, a suitable filler, a lubricant or mold-release  
agent, and a binder, and compressing the mixture in a  
conventional tableting machine into tablets of a pre-  
selected size. Preferably, each tablet will contain from  
5 to 50 milligrams of active ingredient. The tablet can  
20           be scored so that they are easily broken. Optionally, the  
tablets can be coated with tablet-coating materials in  
order to make them more attractive and palatable. They  
can also have enteric coatings so that they will release  
their ingredients slowly and over a longer period.

25           The pharmaceutical carrier in such suspensions or  
syrups can be an aqueous vehicle such as an aromatic  
water, a syrup, or a pharmaceutical mucilage. Suitable  
aromatic waters include the following: Anise Water, N.F.  
(IX); Bitter Almond Water, N.F. (VIII); Camphor Water,  
30           N.F.; Cinnamon Water, U.S.P.; Fennel Water, N.F.; Pepper-

5 mint Water, U.S.P.: Spearmint Water, N.F. (IX); Winter-  
green Water, N.F. (IX). Suitable syrups include the  
following: Syrup (Simple Syrup), U.S.P.; Acacia Syrup,  
U.S.P.; Aromatic Eriodictyon Syrup, N.F.; Aromatic Rhubarb  
Syrup, N.F. (IX); Cacao Syrup, U.S.P.; Cherry Syrup,  
U.S.P.; Cinnamon Syrup, N.F. (IX); Citric Acid Syrup,  
U.S.P.; Compound Sarsaparilla Syrup, N.F.; Compound White  
10 Pine Syrup, N.F.; Ginger Syrup, N.F. (IX); Glycyrrhiza  
(Licorice) Syrup, U.S.P.; Orange Syrup, U.S.P.; Orange  
Flower Syrup, N.F.; Raspberry Syrup, U.S.P.; Rhubarb  
Syrup, N.F. (IX); Tolu Balsam Syrup, U.S.P.; Wild Cherry  
Syrup, U.S.P. Suitable pharmaceutical mucilages include  
the following: Acacia (Gum Arabic), U.S.P.; Acacia  
Mucilage, U.S.P.; Tragacanth, U.S.P.; Tragacanth Mucilage,  
15 N.F. The pharmaceutical carrier in the suspensions or  
syrups can also be a hydroalcoholic vehicle, such as an  
elixir. Suitable elixirs include the following: Aromatic  
Elixir, U.S.P.; Red Aromatic Elixir, N.F.; Glycyrrhiza  
Elixir, N.F.; Iso-Alcoholic Elixir (Iso-Elixir), N.F.  
20 Coloring agents, tinctures, spirits and other adjuvants  
can be admixed with the composition if desired.

25 Typical formulations incorporating the compounds of  
Formula I are described below. These formulations are  
intended to be illustrative merely and no limitation is  
implied or intended.

# TABLET FORMULATION

Formula	Grams per 1000 tablets
Active Ingredient*	20.0
Lactose	270.0
5 Dicalcium phosphate, hydrous	122.5
Polyvinylpyrrolidone	25.0
Polyvinylglycol 1500	7.5
Corn starch	50.0
Magnesium stearate	5.0
	<hr/>
10	500.0

\*Title compound of  
example 1

15 Mix the active ingredient , the lactose and the  
dicalcium phosphate. Dissolve the polyethylene glycol  
1500 and the polyvinylpyrrolidone in approximatelly 20 ml  
of water. Granulate the powder blend with the water  
solution, adding additional water if necessary, to produce  
a damp mass. Pass the wet granulation through a 12 mesh  
20 screen; spread on trays and air dry at 35°C. Blend the  
dry granules with the starch and the magnesium stearate.  
Compress into 500 mg tablets.

0208235

# CAPSULE FORMULATION

	Formula	Grams per 1000 capsules
	Active Ingredient*	20.0
	Lactose	378.0
5	Magnesium stearate	2.0
		<hr/> 400.0

\*Title compound of example 1

Blend the ingredients and fill into hard gelatin capsules.

# ELIXIR FORMULATION

10	Formula	Grams per 1000 liters
	Active Ingredient*	40.0
	Sugar	do 500.0
	Glycerin	do 200.0
15	Compound orange spirit	ml 10.0
	Alcohol	ml 100.0
	Amaranth	ml 0.1
	Water, q.s. 1000.0 ml.	

\*Title compound of example 1



5        Dissolve the active ingredient, the sugar, the glycerin and the amaranth successively in approximately 400 ml of water with the aid of heat. Cool the solution to room temperature. Dissolve the compound orange spirit in the alcohol and add the alcoholic solution to the elixir base. Add sufficient water to make the product measure 1000 ml and agitated until homogeneous. Clarify the elixir by passing it through an asbestos pad, using a filter aid if necessary.

10

#### INJECTION FORMULATION

Formula

Grams per 1000  
ampuls

Active Ingredient\*

110.0

Water for injection, q.s. 1100.0 ml.

15

\*Title compound of example 1

20

Dissolve the active ingredient in the water for injection. Pass the solution through a sterile 0.45 micron membrane filter. Fill aseptically into ampuls (1.1 ml per ampul). Autoclave the sealed ampuls for 30 minutes under 20 p.s.i.g. stream pressure.

In order to achieve a satisfactory response, usually no more than 1 to 3 tablets or capsules as described above need be administered daily. The elixir described is

0208235 ..

usually administered in the amount of 1 to 3 teaspoons (5 cc.) per day while the usual injection dosage is 1 to 3 cc. per day. In severe or aggravated conditions, additional medicine may be administered.


5           As is true for most classes of compounds useful as therapeutic agents not all members have the same biological profile. In the present instance, on the basis of in vitro and in vivo studies, particularly when compared with prior art compounds, it is to be that when  
10       those compounds of Formula I wherein n is 2 such compounds are most preferred. When the R and R<sup>1</sup> groups of the phenalkyl moiety attached directly to the nitrogen atom of the piperidinal moiety are hydrogen and such compounds are preferred. Preferred substituents on the other phenyl  
15       moiety are 4-methoxy, 4-methyl, 3-trifluomethyl, 3,4-dichloro, 3,4-dimethoxy, 3,5-dimethyl and most preferred is when all R groups are hydrogen. Preferred specific compounds are:

20       alpha-phenyl-1-(2-phenethyl)-4-piperidine methanol,  
      alpha-phenyl-1-(3-phenpropyl)-4-piperidine methanol,  
      alpha-(4-methylphenyl)-1-(2-phenethyl)-4-piperidine methanol,  
      alpha-(4-methoxyphenyl)-1-(2-phenethyl)-4-piperidine methanol,  
25       alpha-(3,5 dimethylphenyl)-1-(2-phenethyl)-4-piperidine methanol,  
      alpha-(3-(trifluoromethyl)phenyl)-1-(2-phenethyl)-4-piperidine methanol,  
      alpha-(2,3-dimethoxyphenyl)-1-(2-phenethyl)-4-piperidine  
30       methanol, the first and last named compounds being most preferred.

0208235

C l a i m s

- 1 1. A compound of the general formula (I),



- 2  
3 the optical isomers thereof and the pharmaceutically  
4 acceptable salts thereof wherein n is 2, 3 or 4, each of  
5 R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> independently is hydrogen, halogen,  
6 trifluormethyl, C<sub>1</sub>-6 alkyl, C<sub>1</sub>-6 alkoxy, hydroxy or amino.

- 1 2. A compound of claim 1 wherein n is 2.

- 1 3. A compound of claim 1 wherein n is 3.

- 1 4. A compound of claim 1 wherein R<sup>3</sup> and R<sup>4</sup> are hydrogen.

- 1 5. A compound of claim 4 wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen.

- 1 6. A compound of claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are methoxy  
2 and R<sup>3</sup> and R<sup>4</sup> are hydrogen.

- 1 7. A compound of claim 1 wherein R<sup>1</sup> is methoxy and each  
2 of R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> is hydrogen.


- 1 8. A compound of claim 1 wherein R<sup>1</sup> and R<sup>2</sup> are halogen  
2 and R<sup>3</sup> and R<sup>4</sup> is hydrogen.

9. A compound of claim 1 wherein R is methyl and  $R^2$ ,  $R^3$ ,  $R^4$  are hydrogen.


10. The process for preparing a compound of the general formula (I) according to claim 1

which comprises


A) the chemical reduction of a compound of the formula



B) the alkylation of a compound of the formula





with a reactive derivative having the formula



wherein X is a reactive moiety, preferably a halide, tosylate, mesylate or a functional equivalent thereof, or


(C) the reaction of a Grignard reagent V with an aldehyde of the formula VI



and hydrolyzing the reaction product,





wherein R<sup>1</sup> to R<sup>4</sup> and n are defined as in claim 1.

11. The process for preparing a compound of formula




which comprises


A) the chemical reduction of a compound of the formulae



B) the alkylation of the compound of formula IX



with an alkylating agent of the formula X




wherein the X-substituent is a halide, tosylate, mesylate or a functional equivalent thereof, and

(C) the reaction of a Grignard reagent XI with an aldehyde of the formulae XII



XI



XII

and hydrolyzing the reaction product.

12. A compound of the general formula I according to any of claims 1 to 9 for use as a therapeutical agent.

13. A compound of the general formula I according to any of claims 1 to 9 for use in prophylactically treating migraine.

14. A compound of the general formula I according to any of claims 1 to 9 for use in treating Raymand's phenomenon.

15. A compound of the general formula I according to any of claims 1 to 9 for use in treating variant angina.

16. A compound of the general formula I according to any of claims 1 to 9 for use in treating cardiac arrhythmias.

17. Pharmaceutical composition comprising a compound of the general formula I according to any of claims 1 to 9 and usual carriers and/or additives.





European Patent  
Office

# EUROPEAN SEARCH REPORT

0208235

Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 86108941.3
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
A	US - A - 3 100 775 (RORIG) * Column 1, lines 10-41; column 2, lines 33-36; column 3, lines 46-55; examples 28-30 * --	1,10,17	C 07 D 211/22 A 61 K 31/445
A	GB - A - 1 314 955 (RICHARDSON-MERREL) * Claims 1,5; page 2, line 124 - page 3, line 15 * --	1,10,17	
A	DE - A1 - 2 434 693 (ROBINS) ----		
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)  C 07 D 211/00
Place of search VIENNA		Date of completion of the search 08-10-1986	Examiner HOCHHAUSER
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons  & : member of the same patent family, corresponding document	

EPO Form 1503, 03/87

